Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main (gene editing) focus: Genetic disorders in the liver and nervous system
Company stage: Commercial
Diseases (gene editing): Liver diseases and diseases of the central nervous system
Genome editing tool: ADAR RNA editing, Arcus Meganuclease
Funding stage: Public (NASDAQ:LLY)
Location: Indianapolis, Indiana, USA
Eli Lilly is a big pharma company with several commercialised medicines in its portfolio. The company's involvment in the genome-editing space comes primarily through its collaboration with Precision Biosciences, where Eli Lilly gets access to the ARCUS meganuclease gene-editing technology to treat genetic diseases of muscle, CNS and liver. Another collaboration in this space is with ProQR Therapeutics, where Eli Lilly gains access to an ADAR-based RNA-editing technology.